Lupus Research Alliance
Top-Rated Charity
Website
View similar charities
Ratings & Metrics
Joint Costs
Lupus Research Alliance's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 81% | $14 |
Accounting rules allow charities to report some telemarketing, direct mail, and other solicitation costs as Program expenses. CharityWatch believes that most donors do not consider a charity's solicitation activities to be the Programs they are intending to support with their donations. We therefore adjust such expenses out of a charity's reported Program expense and add it to Fundraising expense prior to calculating its rating.
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| Lupus Research Alliance | IRS Form 990 | 58-2492929 |
| Lupus Research Alliance | Audited Financial Statements | 58-2492929 |
|
Entity: Lupus Research Alliance Document Type: IRS Form 990 Tax ID: 58-2492929 |
|
Entity: Lupus Research Alliance Document Type: Audited Financial Statements Tax ID: 58-2492929 |
Governance & Transparency
CharityWatch evaluates certain criteria related to a charity's Governance and Transparency. Donors may want to consider a charity's willingness to be open and transparent with CharityWatch to be a good litmus test for determining its commitment to public accountability.
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Kenneth M. Farber | Co-CEO/Co-President | $415,380 |
| 2 | Albert Roy | Executive Director, LuCIN | $250,871 |
| 3 | Andrea O'Neill | Executive Director | $227,378 |
|
1 Name: Kenneth M. Farber Title: Co-CEO/Co-President Compensation: $415,380 |
|
2 Name: Albert Roy Title: Executive Director, LuCIN Compensation: $250,871 |
|
3 Name: Andrea O'Neill Title: Executive Director Compensation: $227,378 |
Analysts' Notes
CharityWatch Analysts perform an in-depth analysis of charities' audited financial statements and IRS tax filings, and often review other documents such as state filings, annual reports, and fundraising contracts during their evaluations. Below are select notes that CharityWatch believes may be of interest to donors.
| According to the Lupus Research Alliance audit of December 31, 2017 (Note 1, Organization and Merger): "On July 1, 2016, Lupus Research Institute, Inc. ('LRI') and S.L.E. Lupus Foundation, Inc. (the 'Foundation'), both not-for-profit corporations formed to encourage and support research to discover the causes and cure of Lupus Erythematosus, were merged into the Alliance. At that time, the Organization's name was also changed to Lupus Research Alliance, Inc. The merger allows the Alliance [to] expand its programs. The Alliance paid no consideration in the merger." [...] "At the date of the merger, LRI had $4,000,000 of conditional grants payable. The conditions were satisfied prior to December 31, 2016 and the grants were recognized as expense..." [Note: Click on the "Articles & Alerts" Tab (above) for a link to the July 2016 press release concerning the merger.] Also according to the Lupus Research Alliance audit of December 31, 2017 (Note 13, Subsequent Event): "On January 5, 2018, the Alliance formed Lupus Therapeutics, LLC (the 'LLC'), a single member limited liability company, wholly owned by the Alliance. The LLC was formed to conduct clinical trial studies." |
| According to the Lupus Research Alliance audit of December 31, 2017 (Note 1): "During the years ended December 31, 2017 and 2016, the Alliance received 55% and 31%, respectively, of its contributions from one foundation and one trust." |
| According to the Lupus Research Alliance audit of December 31, 2017 (Note 7b, Promises to Give): "During 2016, the Alliance entered into a collaboration agreement (the 'Agreement') with Centers for Therapeutic Innovation ('CTI') to identify and jointly fund up to three research programs over a two-year period. CTI will contribute up to approximately $610,000 per year over two years to fund this program. The second year contribution of $610,000 is contingent on certain conditions as defined by the Agreement and has not been recorded in the accompanying [audited] financial statements." |